Association of prescription co-payment with adherence to glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor therapies in patients …
Importance Type 2 diabetes (T2D) and heart failure (HF) prevalence are rising in the US.
Although glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose …
Although glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose …
Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the Look AHEAD study
A Elhussein, A Anderson, MP Bancks… - The Lancet Regional …, 2022 - thelancet.com
Background Among patients with type 2 diabetes, minority racial/ethnic groups have a
higher burden of cardiovascular disease, chronic kidney disease, and hypoglycaemia …
higher burden of cardiovascular disease, chronic kidney disease, and hypoglycaemia …
Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity
SW Waldrop, VR Johnson, FC Stanford - Nature Medicine, 2024 - nature.com
Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity | Nature
Medicine Skip to main content Thank you for visiting nature.com. You are using a browser …
Medicine Skip to main content Thank you for visiting nature.com. You are using a browser …
Use of sodium-glucose cotransporter 2 inhibitors and glucagonlike peptide-1 receptor agonists in patients with diabetes and cardiovascular disease in community …
MG Nanna, AA Kolkailah, C Page, ED Peterson… - JAMA …, 2023 - jamanetwork.com
Importance Recent national guidelines recommend sodium-glucose cotransporter 2
inhibitors (SGLT2i) and glucagonlike peptide-1 receptor agonists (GLP-1 RA) in patients …
inhibitors (SGLT2i) and glucagonlike peptide-1 receptor agonists (GLP-1 RA) in patients …
[HTML][HTML] Peer Reviewed: Trends and Predictors of Glycemic Control Among Adults with Type 2 Diabetes Covered by Alabama Medicaid, 2011–2019
CA Presley, Y Khodneva, LD Juarez… - Preventing Chronic …, 2023 - ncbi.nlm.nih.gov
Methods We completed a retrospective analysis of Medicaid claims and laboratory data,
using person-years as the unit of analysis. Inclusion criteria were being aged 19 to 64 years …
using person-years as the unit of analysis. Inclusion criteria were being aged 19 to 64 years …
Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study
Y Yan, Y Gong, M Jiang, Y Gao, S Guo, J Huo… - Frontiers in …, 2023 - frontiersin.org
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been widely used
in treating type 2 diabetes mellitus (T2DM) and obesity in adults, but scientific research …
in treating type 2 diabetes mellitus (T2DM) and obesity in adults, but scientific research …
Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 …
Background Prior studies have shown disparities in the uptake of cardioprotective newer
glucose-lowering drugs (GLDs), including sodium-glucose cotranwsporter-2 inhibitors …
glucose-lowering drugs (GLDs), including sodium-glucose cotranwsporter-2 inhibitors …
Use of lipid-, blood pressure–, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease
AJ Nelson, EC O'Brien, LA Kaltenbach… - JAMA Network …, 2022 - jamanetwork.com
Importance Based on contemporary estimates in the US, evidence-based therapies for
cardiovascular risk reduction are generally underused among patients with type 2 diabetes …
cardiovascular risk reduction are generally underused among patients with type 2 diabetes …
[HTML][HTML] Health insurance and diabetes
SS Casagrande, J Park, WH Herman… - Diabetes in America …, 2023 - ncbi.nlm.nih.gov
National survey data from 2019 indicate that among adults age≥ 18 years with diabetes,
93.4% had health insurance coverage, including 88.9% of those age 18–64 years and …
93.4% had health insurance coverage, including 88.9% of those age 18–64 years and …
Disparities in Postdischarge Ambulatory Care Follow‐Up Among Medicaid Beneficiaries With Diabetes, Hospitalized for Heart Failure
Y Khodneva, EB Levitan, P Arora… - Journal of the …, 2023 - Am Heart Assoc
Background Ambulatory follow‐up for all patients with heart failure (HF) is recommended
within 7 to 14 days after hospital discharge to improve HF outcomes. We examined …
within 7 to 14 days after hospital discharge to improve HF outcomes. We examined …